Local News

• Primovist(R) approved in the U.S. for the detection and characterization of liver lesions  The U.S. Food and Drug Administration has approved Bayer Schering Pharma’s magnetic resonance imaging contrast agent Primovist(R) (gadoxetate disodium) for the detection and characterization of liver lesions in adults with known or suspected focal liver disease.
  Bayer July 08, 2008  
• Cardinal Health formalizes consolidation of businesses  Cardinal Health announced a consolidation of its businesses into two primary operating and reporting segments to reduce costs and align resources with the unique needs of each segment.
  Cardinal Health July 08, 2008  
• FDA grants Invitrogen premarket approval of breast cancer test  Invitrogen announced it has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2 CISH Kit, indicated as an aid in the assessment of breast cancer patients for whom trastuzumab (Herceptin(R)) treatment is being considered.
  Invitrogen Corporation July 08, 2008  
• Herculean device for molecular mysteries  A privately financed team of scientists and engineers is nearing completion of a special-purpose supercomputer intended to offer more than a thousandfold increase in performance for complex molecular simulations.
  The New York Times July 08, 2008  John Markoff
• Wyeth applauds inclusion of the PCV7 vaccine in countries' immunization schedules  Wyeth applauds the countries of Cyprus, Hungary, the Kingdom of Bahrain, Republic of Ireland, Slovak Republic and Sweden for announcing their decisions to routinely immunize infants and young children against pneumococcal disease by adding PREVENAR(TM) PCV7 to their national immunization programs.
  Wyeth July 08, 2008  
• Lilly to acquire SGX Pharmaceuticals  Eli Lilly and Company and SGX Pharmaceuticals announced that the companies have signed a definitive merger agreement providing for the acquisition of SGX in an all-cash transaction.
  Eli Lilly and Company July 08, 2008  
• APP Pharmaceuticals to be acquired by Fresenius  APP Pharmaceuticals and Fresenius SE announced that they have entered into a definitive merger agreement pursuant to which Fresenius will acquire APP. Fresenius will acquire the outstanding common stock of APP for $23.00 in cash per share plus a contingent value right.
  APP Pharmaceuticals, Inc. July 07, 2008  
• Patients more likely to stay on Lipitor than simvastatin, an observational study shows  Pfizer announced that new statin users who took Lipitor(R) were significantly more likely to stay on their medication compared to those who took simvastatin, according to an observational study of more than 186,000 patients in one of the largest U.S. managed care claims databases.
  Pfizer Inc. July 07, 2008  
• Insecticide Movento(R) approved in United States and Canada  The new insecticidal active ingredient spirotetramat from Bayer CropScience has been granted regulatory approval in the strategically important markets in the United States and Canada. Spirotetramat will be marketed worldwide under the brand name Movento(R).
  Bayer July 03, 2008  
• APP receives final approvals for additional dosages of granisetron hydrochloride injection  APP Pharmaceuticals announced that it has received final approvals from the FDA of its Abbreviated New Drug Applications for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL single dose, and 1mg/mL, 4mL multiple dose vials, the generic equivalent of Hoffmann-LaRoche's Kytril(R) Injection.
  APP Pharmaceuticals, Inc. July 03, 2008  

   (next 10 articles)